Catalent (NYSE:CTLT) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Catalent (NYSE:CTLT - Free Report) from a hold rating to a sell rating in a research note published on Tuesday.

A number of other research analysts have also recently commented on CTLT. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a "neutral" rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair reissued a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $63.40.

Catalent Price Performance

NYSE CTLT traded down $0.11 during trading on Tuesday, reaching $62.26. The company's stock had a trading volume of 2,129,004 shares, compared to its average volume of 2,052,697. The firm has a fifty day moving average of $60.10 and a 200 day moving average of $58.80. Catalent has a one year low of $36.74 and a one year high of $62.50. The stock has a market capitalization of $11.30 billion, a PE ratio of -27.60, a P/E/G ratio of 2.46 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the prior year, the business earned ($0.10) earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. Analysts expect that Catalent will post 0.84 EPS for the current fiscal year.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last three months. Corporate insiders own 0.31% of the company's stock.

Hedge Funds Weigh In On Catalent

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group bought a new position in Catalent in the 3rd quarter worth $31,000. Sentry Investment Management LLC bought a new position in shares of Catalent during the 3rd quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC increased its holdings in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock worth $55,000 after acquiring an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company's stock worth $72,000 after purchasing an additional 431 shares in the last quarter. Finally, Intact Investment Management Inc. bought a new stake in shares of Catalent during the 3rd quarter valued at $73,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.